

21 September 2016

ASX Code: MXC

New Medical Cannabis White Paper Developed in Collaboration with University of Sydney Engagement Program

- MGC worked with a University of Sydney Business School industry engagement program to develop a new white paper titled *Clinical Evidence for Medical Cannabis: Epilepsy, Cancer and Multiple Sclerosis*
- This second white paper evaluates current evidence regarding the efficacy of medical cannabis in treating a variety of major diseases
- MGC Pharmaceuticals provided its expertise, contacts and know how developed in the Israeli medical cannabis industry to the Business School's program for the white paper
- Demonstrates MGC's growing leadership in the emerging Australian medical cannabis industry

MGC Pharmaceuticals Ltd (ASX:MXC or "the Company"), is pleased to announce that in collaboration with the University of Sydney Business School community engagement program, it has released a new white paper titled *Clinical Evidence for Medical Cannabis: Epilepsy, Cancer and Multiple Sclerosis*, produced in partnership with MGC Pharmaceuticals.

Following the first MGC Pharmaceuticals/University of Sydney white paper, this paper examined the currently existing evidence supporting the efficacy of medical cannabis in treating a variety of major diseases. The white paper also examined medical cannabis' applicability to relieve associated symptoms for a range of health related issues, including pain, nausea and loss of appetite.

MGC Pharmaceuticals provided its expertise to the Business School program during the study and provided insight into the medical cannabis industry and the Company's experience running clinical trials of new products.

This new white paper can be found by [clicking here](#).

Nativ Segev, Co-founder and Managing Director, MGC Pharmaceuticals commented:

"For medical cannabis to become a trusted treatment option among medical professionals and patients alike, there needs to be rigorous clinical evidence supporting its efficacy. We believe in the potential of medical cannabis more than most, but that belief needs to be proven in the lab under strict conditions.

"MGC Pharmaceuticals is in discussions with leading Australian institutions to provide support and expertise wherever possible, as they strive to increase our understanding of the benefits of medical cannabis and its potential uses as a safe and effective treatment option."

Michael Katz, the University of Sydney Business School lecturer who co-ordinated the study, said:

"Australia has made great advances in paving the way for medical cannabis to be available as a treatment option, but we now need to undertake more research to understand exactly how and why it can be used effectively with patients."

-Ends-

For further information, please contact:

Media Enquiries

Andrew Ramadge
Account Director
Media and Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma CBD cosmetics.